Preferred thinking styles of gifted students and the implications for curriculum development

A sample of 250 students (121) males and (129) females in grades 10-12 participated in this study of their preferred thinking methods. The Methods of Thinking Assessment, which was prepared by Sternberg and Wagner (1991), was used as the data gathering tool. Analysis of data revealed that the preferred methods of thinking were in descending order; legislative, external, hierarchical, judicial, conservative, anarchist, local, internal, monarchic, and global. Also, analysis of data revealed significant differences in all dimensions of the overall score being better for female students; however, no significant differences were found about grade level.Una muestra de 250 estudiantes (121) hombres y (129) mujeres en los grados 10-12 participaron en este estudio de sus métodos de pensamiento preferidos.Los métodos de evaluación del pensamiento que fueron preparados por Sternberg y Wagner (1991) se utilizaron como herramienta de recopilación de datos. El análisis de los datos reveló que los métodos de pensamiento preferidos estaban en orden descendente; legislativo, externo, jerárquico, judicial, conservador, anarquista, local, interno, monárquico y global. Además, el análisis de los datos reveló diferencias significativas en todas las dimensiones de la puntuación general que es mejor para las alumnas

Navigating systemic therapy for metastatic castration-naïve prostate cancer

Introduction: The last decade has seen a remarkable shift in the treatment landscape of advanced prostate cancer, none more so than in the management of metastatic castration-naïve disease.Methods: This narrative review will examine existing and emerging evidence supporting systemic therapy use for metastatic castration-naïve prostate cancer (mCNPC) and provide guidance on the selection of these agents with respect to optimising patient outcomes. Results: The addition of either docetaxel (chemohormonal approach) or an AR pathway inhibitor (abiraterone, enzalutamide or apalutamide) is a reasonable standard of care option for men commencing long-term ADT for mCNPC. While the issue of disease volume as a predictive biomarker for docetaxel benefit has previously been debated, recent data support consideration of upfront docetaxel in all patients, regardless of metastatic burden. Decisions regarding systemic treatment for men with mCNPC should be based on comprehensive consideration of disease, patient and logistical factors. Multiple novel therapeutics for mCNPC are currently under active investigation. Conclusion: The introduction of potent systemic therapy earlier in the mCNPC disease course has resulted in dramatic improvements in clinical outcomes for patients. As the management of mCNPC continues to evolve, the future remains promising, with the expectation of ongoing improvements to patient outcomes and quality of life